SAN DIEGO, April 11 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. , a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, today announced that Evan M. Levine, chief executive officer, will present a corporate overview at the 7th Annual Fortis Biotech Conference on April 25 at 1.45 p.m. British Summer Time (8:45 a.m. Eastern Daylight Time). The conference is being held at the Four Seasons Hotel, Park Lane, London.
A link to the live webcast of the presentation can be accessed via the “Investors” section of the Company’s corporate web site at http://www.adventrx.com under “Events.” The webcast will be made available for replay for 14 days and can be accessed through the same link.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems such as drug metabolism, bioavailability, excessive toxicity and treatment resistance. The Company’s lead product candidate, ANX-510 (CoFactor), is in Phase 3 and Phase 2b clinical trials for the treatment of metastatic colorectal cancer, as well as in a Phase 2 clinical trial for the treatment of advanced breast cancer. More information can be found on the Company’s web site at http://www.adventrx.com.
Forward Looking Statement
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors that, if they do not materialize or prove to be accurate, could cause ADVENTRX’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual results to differ materially include, but are not limited to: uncertainties inherent in the drug development process; the timing and success of clinical trials; the validity of research results; the receipt of necessary approvals from the FDA and other regulatory agencies; and other risks and uncertainties more fully described in ADVENTRX’s press releases and public filings with the Securities and Exchange Commission. ADVENTRX’s public filings with the Securities and Exchange Commission are available at www.sec.gov. ADVENTRX does not intend to update any forward-looking statement, including as set forth in this press release, to reflect events or circumstances arising after the date on which it was made.
ADVENTRX Pharmaceuticals, Inc.
CONTACT: Media, Amy Martini of WeissComm Partners, +1-212-301-7223, forADVENTRX Pharmaceuticals, Inc.; or Investors, Ioana C. Hone of ADVENTRXPharmaceuticals, +1-858-552-0866
Web site: http://www.adventrx.com/
Company News On-Call: http://www.prnewswire.com/gh/cnoc/comp/920134.html/
